Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clarithromycin pulsatile - MiddleBrook

Drug Profile

Clarithromycin pulsatile - MiddleBrook

Alternative Names: Clarithromycin PULSYS™; Pulsatile clarithromycin; PULSYS™ clarithromycin

Latest Information Update: 26 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advancis Pharmaceutical
  • Developer MiddleBrook Pharmaceuticals
  • Class Antibacterials; Macrolides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 26 Aug 2009 No development reported - Phase-I/II for Bacterial infections in USA (PO)
  • 28 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top